Drug
Busulfan clinical trials
Also written Busulfex, CB 2041, GT 41 and Busilvex.
- studies test it
- 322
- open now
- 42
- in phase 3
- 36
- first study started
- 1991
Keep track of what changes. Save the Busulfan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
317 studies that test it; most in 2007 (20); 3 more planned to start later
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1992 | 2 |
| 1993 | 2 |
| 1995 | 3 |
| 1996 | 2 |
| 1997 | 5 |
| 1998 | 8 |
| 1999 | 5 |
| 2000 | 13 |
| 2001 | 5 |
| 2002 | 11 |
| 2003 | 7 |
| 2004 | 13 |
| 2005 | 16 |
| 2006 | 12 |
| 2007 | 20 |
| 2008 | 11 |
| 2009 | 15 |
| 2010 | 17 |
| 2011 | 16 |
| 2012 | 18 |
| 2013 | 17 |
| 2014 | 9 |
| 2015 | 5 |
| 2016 | 13 |
| 2017 | 8 |
| 2018 | 16 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 86
- Phase 2
- 228
- Phase 3
- 36
- Phase 4
- 5
- No phase
- 23
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 317
M.D. Anderson Cancer Center (40) · Masonic Cancer Center, University of Minnesota (20) · Fred Hutchinson Cancer Center (20) · Memorial Sloan Kettering Cancer Center (14) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · National Cancer Institute (NCI) (9) · City of Hope Medical Center (9) · University of California, San Francisco (9)
Often tested with
Tested in the same studies.
Fludarabine (149) · Cyclophosphamide (113) · Melphalan (89) · Fludarabine phosphate (49) · Antilymphocyte Serum (35) · Thiotepa (34) · Etoposide (31) · Tacrolimus (31)
Studies
Open first, then newest update. How each study uses Busulfan is read from its arms, and is right about nine times in ten.
Testing it · 322
- Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07775313Written as Busulfan
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07524530Written as Busulfan
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Busulfan
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)RecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT01306019Written as Busulfan
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT06954987Written as Busulfan
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingPhase 2Fred Hutchinson Cancer CenterNCT03970096Written as Busulfan
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsRecruitingPhase 2National Cancer Institute (NCI)NCT01861106Written as Busulfan (Busulfex)
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06851767Written as Busulfan
- CD34+ Enriched Transplants to Treat Myelodysplastic SyndromeNot yet recruitingNot applicableGuenther KoehneNCT05617625Written as Busulfan
- CD34+ Transplants for Myeloid MalignanciesNot yet recruitingPhase 2Guenther KoehneNCT05565105Written as Busulfan
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07113743Written as Busulfan
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaRecruitingPhase 2/3St. Anna KinderkrebsforschungNCT01949129Written as Busulfan
- 26DT052; Scaling Busulfan Dose to Body Surface Area in ChildrenNot yet recruitingPhase 1Children's Hospital of PhiladelphiaNCT07792369Written as Busulfan (BU)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as Busulfan
- A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT07762508Written as Busulfan (BU)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709Written as Busulfan
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingPhase 2/3M.D. Anderson Cancer CenterNCT04708054Written as Busulfan
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06959771Written as Busulfan
- Personalized NK Cell Therapy in CBTRecruitingPhase 2M.D. Anderson Cancer CenterNCT02727803Written as Busulfan
- Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)RecruitingPhase 2University of Illinois at ChicagoNCT06802315Written as Busulfan (conditioning for ALLO Transplant)
See all 322 studies that test Busulfan →
Given in every arm · 105 — Busulfan is usual care beside what is tested
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingPhase 2National Cancer Institute (NCI)NCT04339777Written as Busulfan
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07228624Written as Busulfan
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT05327023Written as Busulfan
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) SyndromeRecruitingPhase 2National Cancer Institute (NCI)NCT05027945Written as Busulfan
- Gene Editing For Sickle Cell DiseaseRecruitingPhase 1St. Jude Children's Research HospitalNCT06506461Written as Busulfan
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) AntagonistsRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05463133Written as Busulfan
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06345495Written as Busulfan
- Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)RecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT07183878Written as Busulfan (BU)
- Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic MalignanciesRecruitingPhase 1Sawa Ito, MDNCT07565220Written as Busulfan
- Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple MyelomaNot yet recruitingPhase 1University of California, DavisNCT07759102Written as Busulfan
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06207799Written as Busulfan
- Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic SyndromeNot yet recruitingPhase 1University of Michigan Rogel Cancer CenterNCT07737769Written as Busulfan
- Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)RecruitingNot applicableMasonic Cancer Center, University of MinnesotaNCT01666080Written as Busulfan
- Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06996119Written as Busulfan
- Allo HSCT for High Risk HemoglobinopathiesRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06872333Written as Busulfan
- Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCTRecruitingPhase 2Nantes University HospitalNCT05917405Written as Busulfan
- VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCTNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07052422Written as Busulfan (Bu)
- A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple SclerosisNot yet recruitingPhase 1Stanford UniversityNCT06900192Written as myeloablative regimen
- Twice-per-weekSelinexor, 2 Days MelphalanNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT06613035Written as Intravenous Busulfan
- Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MRNot yet recruitingPhase 3Ruijin HospitalNCT06297772Written as Busulfan Injection
Showing 20 of 105.
As the comparator · 8 — what is tested is compared with Busulfan
- Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft TransplantationRecruitingPhase 2Nantes University HospitalNCT06252870Written as Busulfan
- Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic SyndromeEnrolling by invitationPhase 3Wuhan Union Hospital, ChinaNCT05674539Written as Fludarabine and Busulfan
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingPhase 3St. Anna KinderkrebsforschungNCT01704716Written as Busulfan
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06079879Written as Busulfan
- Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)Active, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT03597594Written as Busulfan
- Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant DiseasesCompletedPhase 2medac GmbHNCT02349906Written as Busilvex
- Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant DiseasesCompletedPhase 2/3Columbia UniversityNCT01019876Written as Busulfan
- Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)CompletedPhase 3medac GmbHNCT00822393Written as Busulfan
Codes
What other systems call Busulfan · ClinicalTrials.gg INT007102
- MeSH (NLM) D002066BusulfanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G1LN9045DKBUSULFANConfirmed FDA, NLM, Wikidata
- RxNorm 1828Confirmed FDA, Wikidata
- Wikidata Q348922busulfanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C321BusulfanOne source FDA
- DrugBank DB01008One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D002066 | Busulfan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G1LN9045DK | BUSULFAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1828 | — | Confirmed FDA, Wikidata |
| Wikidata | Q348922 | busulfan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C321 | Busulfan | One source FDA |
| DrugBank | DB01008 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.